If you’re looking at treatment options for type 2 diabetes, you may want to learn more about Trulicity (dulaglutide). It’s a prescription drug used in adults to help with the following: Trulicity ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...

(Reuters) - Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with ...

SAN FRANCISCO -- The GLP-1 receptor agonist dulaglutide (Trulicity) slowed renal function decline in some patients with type 2 diabetes and poor kidney functioning, researchers said here, and they ...

Eli Lilly has re-entered the GLP-1 class of diabetes treatment following the US approval of Trulicity. The FDA gave the green light to the drug to improve glycaemic control in adults with type 2 ...

(Reuters) - Eli Lilly and Co <LLY.N> third-quarter sales missed Wall Street estimates on Wednesday as rebates limited revenue from its top-selling diabetes drug Trulicity, and its shares fell about 4% ...

Dec 16 (Reuters) - The U.S. health regulator has added Eli Lilly and Co's (LLY.N), opens new tab Mounjaro to its list of drugs facing shortages, highlighting the company's struggles to meet booming ...

Trulicity (dulaglutide) is a prescription drug used to treat type 2 diabetes and lower certain cardiovascular risks. This drug can interact with other medications and some supplements. For example, ...

AbbVie’s JAK inhibitor Rinvoq wasn’t even in the top 10 for pharma TV ad spending in February, but it shot up to first place in March as Eli Lilly’s Trulicity dropped down to fifth. Rinvoq is a follow ...